JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Edgar, D. M.
Right arrow Articles by Wood, P. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Edgar, D. M.
Right arrow Articles by Wood, P. L.

Vol. 282, Issue 1, 420-429, 1997

CCD-3693: An Orally Bioavailable Analog of the Endogenous Neuroactive Steroid, Pregnanolone, Demonstrates Potent Sedative Hypnotic Actions in the Rat

Dale M. Edgar, Wesley F. Seidel, Kelvin W. Gee, Nancy C. Lan, George Field, Haiji Xia, Jon E. Hawkinson, Scott Wieland, Richard B. Carter and Paul L. Wood

Sleep Research Center, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford (D.M.E., W.F.S.); Department of Pharmacology, College of Medicine, University of California, Irvine (K.W.G.); and CoCensys Inc., Irvine, California (N.C.L., G.F., H.X., J.E.H., S.W., R.B.C., P.L.W.)

An endogenous neuroactive steroid, pregnanolone, and an orally available synthetic analog, CCD-3693, were administered to rats at the middle of their circadian activity phase (6 hr after lights off). Electroencephalogram-defined sleep-wake states, locomotor activity and body temperature were concurrently measured 30 hr before and after treatment. Identical procedures were used to test triazolam and zolpidem. Triazolam (0.1-1.6 mg/kg), zolpidem (2.5-10 mg/kg) and the neuroactive steroids (10-30 mg/kg) produced dose-dependent increases in non-rapid eye movement (NREM) sleep. At this dose and time of day (in which the rats were predominantly awake during the 6 hr before treatment) the neuroactive steroids appeared more intrinsically efficacious in promoting NREM sleep than the benzodiazepine ligands. The neurosteroids did not, however, significantly interfere with rapid eye movement sleep and were more selective in reducing (EEG) wakefulness, with relatively less locomotor activity impairment during waking than triazolam and zolpidem. In addition, the benzodiazepine receptor ligands showed distinct "rebound" wakefulness after the NREM sleep-promoting effect subsided, although the neuroactive steroids did not. In addition, in vitro binding studies and in vivo pharmacological data confirmed that CCD-3693 was orally active in standard tests of anxiety, anticonvulsant, loss-of-righting and passive avoidance.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
J.-M. I. Alakoskela, T. Soderlund, J. M. Holopainen, and P. K. J. Kinnunen
Dipole Potential and Head-Group Spacing Are Determinants for the Membrane Partitioning of Pregnanolone
Mol. Pharmacol., July 1, 2004; 66(1): 161 - 168.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. E. Vanover, S. Rosenzweig-Lipson, J. E. Hawkinson, N. C. Lan, J. D. Belluzzi, L. Stein, J. E. Barrett, P. L. Wood, and R. B. Carter
Characterization of the Anxiolytic Properties of a Novel Neuroactive Steroid, Co 2-6749 (GMA-839; WAY-141839; 3alpha , 21-Dihydroxy-3beta -trifluoromethyl-19-nor-5beta -pregnan-20-one), a Selective Modulator of gamma -Aminobutyric AcidA Receptors
J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 337 - 345.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Lancel and A. Langebartels
gamma -Aminobutyric AcidA (GABAA) Agonist 4,5,6,7-Tetrahydroisoxazolo[4,5-c]pyridin-3-ol Persistently Increases Sleep Maintenance and Intensity during Chronic Administration to Rats
J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 1084 - 1090.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. E. Vanover, D. M. Edgar, W. F. Seidel, D. J. Hogenkamp, D. B. Fick, N. C. Lan, K. W. Gee, and R. B. Carter
Response-Rate Suppression in Operant Paradigm as Predictor of Soporific Potency in Rats and Identification of Three Novel Sedative-Hypnotic Neuroactive Steroids
J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1317 - 1323.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. E. Hawkinson, M. Acosta-Burruel, K. C. Yang, D. J. Hogenkamp, J.-S. Chen, N. C. Lan, J. A. Drewe, E. R. Whittemore, R. M. Woodward, R. B. Carter, et al.
Substituted 3beta -Phenylethynyl Derivatives of 3alpha -Hydroxy-5alpha -pregnan-20-one: Remarkably Potent Neuroactive Steroid Modulators of gamma -Aminobutyric AcidA Receptors
J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 198 - 207.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. F. Olive, W. F. Seidel, and D. M. Edgar
Compensatory Sleep Responses to Wakefulness Induced by the Dopamine Autoreceptor Antagonist (-)DS121
J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1073 - 1083.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. M. Edgar and W. F. Seidel
Modafinil Induces Wakefulness Without Intensifying Motor Activity or Subsequent Rebound Hypersomnolence in the Rat
J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 757 - 769.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.